Molecular models to characterize actions of calcium sensitizing drugs

表征钙增敏药物作用的分子模型

基本信息

  • 批准号:
    10307610
  • 负责人:
  • 金额:
    $ 36.29万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-01-15 至 2024-11-30
  • 项目状态:
    已结题

项目摘要

Project Summary / Abstract Heart failure is a pressing problem in today’s society. Positive inotropic agents are needed in the treatment of heart failure due to left ventricular systolic dysfunction. Many of the currently used drugs (such as β-adrenergic agonists and phosphodiesterase III inhibitors) are ineffective in the long-term since they are plagued with severe side effects. Calcium sensitizing agents are interesting alternative drug candidates if they can cause a positive inotropic effect without associated side effects. One possible target for calcium sensitizing drugs is cardiac troponin (cTn), a Ca2+-dependent switch, activating and deactivating the myofilament leading to contraction and relaxation. Cardiac cTn consists of three subunits: cTnC, cTnI and cTnT. Increasingly routine computational methods are used to study cTn. However, there remains a critical need for development of novel and more precise tools that expand understanding of molecular processes governing heart contraction in order to guide targeted drug discovery studies. The main objective of this proposal is to develop novel computational methods to predict and modulate calcium sensitization within cTnC. Results from computational method advances will be verified experimentally and the experimental results will drive additional method refinement. The proposed research is structured into three main stages. We will use computer-aided drug design studies to find and experimentally verify novel calcium sensitizing agents (Aim I) and then develop computational models to understand the molecular processes in cTn that underlie the observed sensitizing effect with direct feedback to experiments (Aims II and III). Method development work will focus on overcoming two main hurdles faced by current computational models of cardiomyocyte contraction. Firstly, we will develop new methodology to accurately predict calcium binding affinities to cTnC (Aim II). Based on strong preliminary data, we hypothesize that this requires polarizable force fields, without which Ca2+ binding is not adequately modeled and oversimplified in molecular dynamics (MD) simulations. Secondly, we will predict the degree to which drugs open up the cTnC-cTnI interface (Aim III). Based on preliminary data, our hypothesis is that microsecond MD simulations and new methodology are needed to determine the opening degree of the hydrophobic patch in drug-bound conformations. Results from computational method advances will be verified experimentally and the experimental results will drive additional method refinement and improve our initial drug discovery hits.
项目概要/摘要 心力衰竭是当今社会的一个紧迫问题。需要正性肌力药物 治疗左心室收缩功能障碍所致的心力衰竭。目前使用的许多药物 (如β-肾上腺素能激动剂和磷酸二酯酶III抑制剂)长期无效 因为它们受到严重副作用的困扰。钙敏化剂是有趣的替代品 候选药物是否可以引起正性肌力作用而不产生相关副作用。一 钙增敏药物的可能目标是心肌肌钙蛋白 (cTn),一种 Ca2+ 依赖性开关, 激活和停用肌丝,导致收缩和放松。心脏肌钙蛋白 由三个亚基组成:cTnC、cTnI 和 cTnT。越来越常规的计算方法是 用于研究 cTn。然而,仍然迫切需要开发新颖且更精确的 扩大对控制心脏收缩的分子过程的理解的工具,以指导 靶向药物发现研究。该提案的主要目标是开发新颖的 预测和调节 cTnC 内钙敏化的计算方法。结果 计算方法的进步将得到实验验证,并且实验 结果将推动进一步的方法改进。拟议的研究分为三个部分 主要阶段。我们将使用计算机辅助药物设计研究来寻找并通过实验验证新颖的药物 钙敏化剂(目标 I),然后开发计算模型来了解 cTn 中的分子过程是观察到的敏化效应的基础,并直接反馈到 实验(目标 II 和 III)。方法开发工作将侧重于克服两个主要障碍 面临当前心肌细胞收缩的计算模型。首先,我们将开发新的 准确预测钙与 cTnC 结合亲和力的方法(目标 II)。立足于强 初步数据,我们假设这需要极化力场,没有Ca2+ 在分子动力学(MD)模拟中,结合没有得到充分的建模和过度简化。 其次,我们将预测药物打开 cTnC-cTnI 界面的程度(目标 III)。基于 根据初步数据,我们的假设是微秒MD模拟和新方法是 需要确定药物结合构象中疏水补片的开放程度。 计算方法进步的结果将通过实验进行验证,并且实验 结果将推动进一步的方法改进并提高我们最初的药物发现命中率。

项目成果

期刊论文数量(22)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Computational Methods Elucidate Consequences of Mutations and Post-translational Modifications on Troponin I Effective Concentration to Troponin C.
Adaptative Steered Molecular Dynamics Study of Mutagenesis Effects on Calcium Affinity in the Regulatory Domain of Cardiac Troponin C.
Computational Exploration and Characterization of Potential Calcium Sensitizing Mutations in Cardiac Troponin C.
Accurately Predicting Disordered Regions of Proteins Using Rosetta ResidueDisorder Application.
Umbrella Sampling Simulations Measure Switch Peptide Binding and Hydrophobic Patch Opening Free Energies in Cardiac Troponin.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Steffen Lindert其他文献

Steffen Lindert的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Steffen Lindert', 18)}}的其他基金

Computational Tools for Protein Complex Structure Prediction from MS Data
根据 MS 数据预测蛋白质复杂结构的计算工具
  • 批准号:
    10441403
  • 财政年份:
    2018
  • 资助金额:
    $ 36.29万
  • 项目类别:
Computational Tools for Protein Complex Structure Prediction from MS Data
根据 MS 数据预测蛋白质复杂结构的计算工具
  • 批准号:
    10192753
  • 财政年份:
    2018
  • 资助金额:
    $ 36.29万
  • 项目类别:
Molecular models to characterize actions of calcium sensitizing drugs
表征钙增敏药物作用的分子模型
  • 批准号:
    10063891
  • 财政年份:
    2018
  • 资助金额:
    $ 36.29万
  • 项目类别:
Rational Drug Design for Chronic Neuronal Damage
针对慢性神经元损伤的合理药物设计
  • 批准号:
    9550891
  • 财政年份:
    2017
  • 资助金额:
    $ 36.29万
  • 项目类别:
Computational Tools for Protein Complex Structure Prediction from MS Data
根据 MS 数据预测蛋白质复杂结构的计算工具
  • 批准号:
    9978851
  • 财政年份:
  • 资助金额:
    $ 36.29万
  • 项目类别:

相似海外基金

Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
  • 批准号:
    8358448
  • 财政年份:
    2012
  • 资助金额:
    $ 36.29万
  • 项目类别:
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
  • 批准号:
    8517552
  • 财政年份:
    2012
  • 资助金额:
    $ 36.29万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7952159
  • 财政年份:
    2009
  • 资助金额:
    $ 36.29万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7952152
  • 财政年份:
    2009
  • 资助金额:
    $ 36.29万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7719194
  • 财政年份:
    2008
  • 资助金额:
    $ 36.29万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7605416
  • 财政年份:
    2007
  • 资助金额:
    $ 36.29万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7605425
  • 财政年份:
    2007
  • 资助金额:
    $ 36.29万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7378753
  • 财政年份:
    2006
  • 资助金额:
    $ 36.29万
  • 项目类别:
Adrenergic Agents for Methamphetamine: Outpatient Trials
甲基苯丙胺肾上腺素药物:门诊试验
  • 批准号:
    6825160
  • 财政年份:
    2004
  • 资助金额:
    $ 36.29万
  • 项目类别:
ADRENERGIC AGENTS FOR CARDIOPULMONARY RESUSCITATION
用于心肺复苏的肾上腺素能药物
  • 批准号:
    2702283
  • 财政年份:
    1997
  • 资助金额:
    $ 36.29万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了